These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 35156542)

  • 1. Contextual Parameters Associated with Positive and Negative Mental Health in Recreational Psychedelic Users.
    St Arnaud KO; Sharpe D
    J Psychoactive Drugs; 2023; 55(1):30-39. PubMed ID: 35156542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations between lifetime classic psychedelic use and markers of physical health.
    Simonsson O; Sexton JD; Hendricks PS
    J Psychopharmacol; 2021 Apr; 35(4):447-452. PubMed ID: 33719688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are you tripping comfortably? Investigating the relationship between harm reduction and the psychedelic experience.
    Palmer M; Maynard OM
    Harm Reduct J; 2022 Jul; 19(1):81. PubMed ID: 35871679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Personality traits explain the relationship between psychedelic use and less depression in a comparative study.
    Sjöström DK; Claesdotter-Knutsson E; Kajonius PJ
    Sci Rep; 2024 May; 14(1):10195. PubMed ID: 38702496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Why psychiatry needs psychedelics and psychedelics need psychiatry.
    Sessa B
    J Psychoactive Drugs; 2014; 46(1):57-62. PubMed ID: 24830186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microdosing psychedelics: Motivations, subjective effects and harm reduction.
    Lea T; Amada N; Jungaberle H; Schecke H; Klein M
    Int J Drug Policy; 2020 Jan; 75():102600. PubMed ID: 31778967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psychedelic pleasures: An affective understanding of the joys of tripping.
    Bøhling F
    Int J Drug Policy; 2017 Nov; 49():133-143. PubMed ID: 28918193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alternative beliefs in psychedelic drug users.
    Lebedev AV; Acar K; Horntvedt O; Cabrera AE; Simonsson O; Osika W; Ingvar M; Petrovic P
    Sci Rep; 2023 Sep; 13(1):16432. PubMed ID: 37777572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From Egoism to Ecoism: Psychedelics Increase Nature Relatedness in a State-Mediated and Context-Dependent Manner.
    Kettner H; Gandy S; Haijen ECHM; Carhart-Harris RL
    Int J Environ Res Public Health; 2019 Dec; 16(24):. PubMed ID: 31888300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case analysis of long-term negative psychological responses to psychedelics.
    Bremler R; Katati N; Shergill P; Erritzoe D; Carhart-Harris RL
    Sci Rep; 2023 Sep; 13(1):15998. PubMed ID: 37749109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perceived outcomes of psychedelic microdosing as self-managed therapies for mental and substance use disorders.
    Lea T; Amada N; Jungaberle H; Schecke H; Scherbaum N; Klein M
    Psychopharmacology (Berl); 2020 May; 237(5):1521-1532. PubMed ID: 32043165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recreational use of psychedelics is associated with elevated personality trait openness: Exploration of associations with brain serotonin markers.
    Erritzoe D; Smith J; Fisher PM; Carhart-Harris R; Frokjaer VG; Knudsen GM
    J Psychopharmacol; 2019 Sep; 33(9):1068-1075. PubMed ID: 30816797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Typology of Users of Psychedelics and Alike Psychoactive Substances in Czechia: Results of the National Online Survey.
    Kňažek F; Horák M; Ocetková T; Somerlíková K; Bláhová B; Plevková M; Mravčík V; Chomynová P; Kočárová R
    J Psychoactive Drugs; 2023; 55(5):601-611. PubMed ID: 36827494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psychologists' and psychotherapists' knowledge, attitudes, and clinical practices regarding the therapeutic use of psychedelics.
    Kucsera A; Suppes T; Haug NA
    Clin Psychol Psychother; 2023; 30(6):1369-1379. PubMed ID: 37394242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psychedelic experience dose-dependently modulated by cannabis: results of a prospective online survey.
    Kuc J; Kettner H; Rosas F; Erritzoe D; Haijen E; Kaelen M; Nutt D; Carhart-Harris RL
    Psychopharmacology (Berl); 2022 May; 239(5):1425-1440. PubMed ID: 34734314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psychedelic drug use and schizotypy in young adults.
    Lebedev AV; Acar K; Garzón B; Almeida R; Råback J; Åberg A; Martinsson S; Olsson A; Louzolo A; Pärnamets P; Lövden M; Atlas L; Ingvar M; Petrovic P
    Sci Rep; 2021 Jul; 11(1):15058. PubMed ID: 34301969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psychedelics not linked to mental health problems or suicidal behavior: a population study.
    Johansen PØ; Krebs TS
    J Psychopharmacol; 2015 Mar; 29(3):270-9. PubMed ID: 25744618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Gratuitous Grace: The Influence of Religious Set and Intent on the Psychedelic Experience.
    Neitzke-Spruill L; Glasser C
    J Psychoactive Drugs; 2018; 50(4):314-321. PubMed ID: 30052496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Viability of Microdosing Psychedelics as a Strategy to Enhance Cognition and Well-being - An Early Review.
    Bornemann J
    J Psychoactive Drugs; 2020; 52(4):300-308. PubMed ID: 32362269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ethical and legal issues in psychedelic harm reduction and integration therapy.
    Pilecki B; Luoma JB; Bathje GJ; Rhea J; Narloch VF
    Harm Reduct J; 2021 Apr; 18(1):40. PubMed ID: 33827588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.